Compounds that targeted BET ((+)-JQ1) and JMJD3 (GSKJ4) have been recently described as promising compounds for GBM and pediatric GBM [24–26], and therefore we decided to not pursue them further. The gene discussed is DNER; the disease is glioblastoma.